Compared with standard AUD medications, the use of semaglutide and liraglutide was linked to a lower risk for alcohol use ...

The popular glucagon-like peptide-1 (GLP-1) receptor agonists known to help in weight loss as well as manage blood sugar can ...

About 42% of U.S. adults are obese, the CDC says. GLP-1 medications have changed the picture for people hoping to reduce ...

The biggest and most comprehensive analysis of glucagon-like peptide-1 (GLP-1) receptor agonists on kidney and cardiovascular ...

The Biden administration has proposed a new plan to expand coverage of glucagon-like peptide-1 (GLP-1) medications such as ...

The Centers for Medicare and Medicaid Services draft regulation also would introduce Medicare and Medicaid coverage of ...

The Biden administration wants to expand coverage of anti-obesity medications to millions on Medicare, Medicaid.

TennCare is federally required to cover GLP-1 drugs; of the $118M in the cost increase request, more than $76 million would ...

The glucose-lowering and weight-reducing drug class appears to benefit the heart and kidneys in people with lupus and lupus nephritis, independently of glucose-lowering and weight loss.

Those on the medications, known as GLP-1s or glucagon-like peptide-1, will additionally weigh in four times a month on "smart ...

The combined reduction in the risk of kidney failure, worsening kidney function and death due to kidney disease was 19%, ...

A multistate model that enables real-time risk recalculations may help improve risk stratification for prediction of ...